These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 36147461)

  • 1. Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.
    Cao H; Huang T; Dai M; Kong X; Liu H; Zheng Z; Sun G; Sun G; Rong D; Jin Z; Tang W; Xia Y
    Int J Biol Sci; 2022; 18(14):5369-5390. PubMed ID: 36147461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.
    Liu D; Heij LR; Czigany Z; Dahl E; Lang SA; Ulmer TF; Luedde T; Neumann UP; Bednarsch J
    J Exp Clin Cancer Res; 2022 Apr; 41(1):127. PubMed ID: 35392957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).
    Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H
    Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
    Rimassa L; Personeni N; Aghemo A; Lleo A
    J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholangiocarcinoma: what are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells?
    Wang J; Loeuillard E; Gores GJ; Ilyas SI
    Expert Opin Ther Targets; 2021 Oct; 25(10):835-845. PubMed ID: 34806500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of tumour microenvironment: a new vision for cholangiocarcinoma.
    Chen Z; Guo P; Xie X; Yu H; Wang Y; Chen G
    J Cell Mol Med; 2019 Jan; 23(1):59-69. PubMed ID: 30394682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts.
    Raggi C; Invernizzi P; Andersen JB
    J Hepatol; 2015 Jan; 62(1):198-207. PubMed ID: 25220250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-Associated Fibroblasts and Extracellular Matrix: Therapeutical Strategies for Modulating the Cholangiocarcinoma Microenvironment.
    Minini M; Fouassier L
    Curr Oncol; 2023 Apr; 30(4):4185-4196. PubMed ID: 37185432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Functional Roles of Immune Cells in Primary Liver Cancer.
    Pham L; Kyritsi K; Zhou T; Ceci L; Baiocchi L; Kennedy L; Chakraborty S; Glaser S; Francis H; Alpini G; Sato K
    Am J Pathol; 2022 Jun; 192(6):826-836. PubMed ID: 35337836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy.
    Louis C; Edeline J; Coulouarn C
    Expert Opin Ther Targets; 2021 Feb; 25(2):153-162. PubMed ID: 33502260
    [No Abstract]   [Full Text] [Related]  

  • 11. Heterogeneity of Cholangiocarcinoma Immune Biology.
    Vita F; Olaizola I; Amato F; Rae C; Marco S; Banales JM; Braconi C
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholangiocarcinoma - novel biological insights and therapeutic strategies.
    Ilyas SI; Affo S; Goyal L; Lamarca A; Sapisochin G; Yang JD; Gores GJ
    Nat Rev Clin Oncol; 2023 Jul; 20(7):470-486. PubMed ID: 37188899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses.
    Xia T; Li K; Niu N; Shao Y; Ding D; Thomas DL; Jing H; Fujiwara K; Hu H; Osipov A; Yuan C; Wolfgang CL; Thompson ED; Anders RA; He J; Mou Y; Murphy AG; Zheng L
    J Hematol Oncol; 2022 Mar; 15(1):37. PubMed ID: 35346322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-associated macrophages: orchestrators of cholangiocarcinoma progression.
    Chen F; Sheng J; Li X; Gao Z; Hu L; Chen M; Fei J; Song Z
    Front Immunol; 2024; 15():1451474. PubMed ID: 39290697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy and targeted therapy for cholangiocarcinoma: Artificial intelligence research in imaging.
    Liu J; Shu J
    Crit Rev Oncol Hematol; 2024 Feb; 194():104235. PubMed ID: 38220125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances and considerations in the use of immunotherapies for primary hepato-biliary malignancies.
    Gorji L; Brown ZJ; Pawlik TM
    Surg Oncol; 2024 Feb; 52():102031. PubMed ID: 38128340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications.
    Wu HJ; Chu PY
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-infiltrating T lymphocytes: A promising immunotherapeutic target for preventing immune escape in cholangiocarcinoma.
    Hua S; Gu X; Jin H; Zhang X; Liu Q; Yang J
    Biomed Pharmacother; 2024 Aug; 177():117080. PubMed ID: 38972151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
    Zhang Q; Lou Y; Bai XL; Liang TB
    World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma.
    Alnaggar M; Xu Y; Li J; He J; Chen J; Li M; Wu Q; Lin L; Liang Y; Wang X; Li J; Hu Y; Chen Y; Xu K; Wu Y; Yin Z
    J Immunother Cancer; 2019 Feb; 7(1):36. PubMed ID: 30736852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.